Proton Therapy Pediatric denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for proton therapy pediatric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Pediatric Proton Therapy as Experimental

Aetna's clinical policy distinguishes between tumor types and patient populations where it considers proton beam therapy established versus investigational. For certain pediatric diagnoses, Aetna's policy may classify proton therapy as experimental or investigational when the plan's reviewers conclude that the evidence base does not yet meet the plan's threshold for established clinical benefit. This is one of the most common — and most frequently overturned — denial categories for pediatric proton therapy.

## Why This Denial Is Appealable

Proton therapy is FDA-cleared radiation delivery technology, not an experimental drug or device in the regulatory sense. The experimental label in a coverage policy is a plan-specific utilization management determination, not a medical or regulatory finding. For pediatric tumors, the clinical rationale often rests on physics — the Bragg peak dose distribution — and on the well-documented concern about late radiation effects in children, which is a recognized clinical distinction. The appeal should squarely address Aetna's specific policy criteria and demonstrate that this patient's situation meets the conditions under which Aetna does consider proton therapy established.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Request the specific clinical policy number and the credentials of the reviewing clinician.
• External review (ACA §2719): Available after an adverse internal determination. An accredited IRO reviews the medical evidence independently; its decision binds the plan.
• ERISA §503: For employer-sponsored plans, the plan must provide the specific reasons for denial and allow you to review and respond to any new evidence used in the appeal.
• Expedited review: Available when delay would seriously jeopardize the child's health — request it in writing at the same time as the standard appeal.
• Timeline: Initiate external review within four months of the final internal denial.

## Documentation to Gather

• Diagnosis and staging: Complete pathology, imaging, and multidisciplinary tumor board notes.
• Radiation oncologist's medical-necessity letter: Should directly address each criterion in Aetna's clinical policy and explain why proton therapy is not experimental for this specific indication in a pediatric patient.
• Dosimetric comparison plan: A treatment-planning comparison showing the dose to organs at risk under proton versus photon plans, prepared by the treating center's physics team.
• Pediatric subspecialty support: Letters or chart notes from the pediatric oncologist confirming the treatment recommendation.
• Applicable guideline organization references: Cite the relevant professional society (such as ASTRO or the applicable COG guidance) generically to support that the treatment is within recognized clinical practice.

## Criteria-Mapping Structure

Download Aetna's current clinical policy bulletin for proton beam therapy. List every criterion under which Aetna considers the treatment established (non-experimental) for pediatric patients. For each criterion, write the exact chart fact that satisfies it, with the source document, date, and author. If the denial letter cited a specific evidence standard, address it directly in the appeal letter. The IRO reviewer will compare the plan's own policy against the submitted evidence — make that comparison as easy as possible by formatting your submission as a point-by-point response.